Medicus Pharma prices $7M public offering of 2.26M units at $3.10/unit; closes June 2

Medicus Pharma Ltd.

Gross proceeds $7,006,000 from 2,260,000 units at $3.10/unit; each unit = 1 common share + 1 warrant.
Warrants exercisable at $3.10/share, expire 5 years from issuance; not listed on exchange.
Net proceeds to fund Phase 2 proof-of-concept trial for basal cell carcinoma using doxorubicin tip loaded dissolvable microarray needle skinpatch.
Co. also issued $1.25M second-tranche debenture to Yorkville on June 2, 2025, bringing total Yorkville debentures to $2.5M.
Placement agents Maxim, Brookline, D. Boral; cash fee 7.5% of gross proceeds.

item 1.01item 3.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.